OVERSEA CHINESE BANKING Corp Ltd Takes Position in Stryker Corporation $SYK

OVERSEA CHINESE BANKING Corp Ltd bought a new stake in Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,877 shares of the medical technology company’s stock, valued at approximately $906,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of SYK. Gables Capital Management Inc. acquired a new position in Stryker in the second quarter valued at $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth about $26,000. Sankala Group LLC acquired a new stake in shares of Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker during the third quarter worth about $27,000. Finally, Atlas Capital Advisors Inc. purchased a new position in shares of Stryker during the fourth quarter worth about $27,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 665,370 shares of company stock worth $216,238,501 in the last quarter. Company insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $329.86 on Friday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a 50-day simple moving average of $326.99 and a 200-day simple moving average of $332.64. The company has a market capitalization of $126.52 billion, a PE ratio of 34.18, a P/E/G ratio of 2.09 and a beta of 0.76.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the firm earned $3.13 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is 36.48%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analyst Upgrades and Downgrades

Several research firms have commented on SYK. Evercore set a $350.00 price objective on Stryker in a research note on Monday, July 6th. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. JPMorgan Chase & Co. dropped their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Raymond James Financial set a $370.00 price target on Stryker in a research note on Friday, July 31st. Finally, Needham & Company LLC decreased their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.